How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about selpercatinib

Marketing authorisation indication and anticipated marketing authorisation indication

2.1

Selpercatinib (Retevmo, Eli Lilly) is indicated for 'the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer'.

2.2

Selpercatinib also received a marketing authorisation by the European Commission for 'the treatment of adults and adolescents 12 years and older with advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate)', but it does not have a marketing authorisation in Great Britain for this indication yet.

Price

2.4

The list price for selpercatinib is £2,184 per pack of 56 40‑mg capsules, and £4,368 per pack of 56 80‑mg tablets.

2.5

The company has a commercial arrangement. This makes selpercatinib available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.